Want to see KR:004720 full AI Analyst Report?
PharmGen Science, Inc. (004720) Financial Statements
PharmGen Science, Inc. Financial Overview
PharmGen Science, Inc.'s market cap is currently $62.52B. The company's EPS TTM is $-6137.00; its P/E ratio is -0.45; PharmGen Science, Inc. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 173.07B | $ 171.29B | $ 166.78B | $ 150.93B | $ 109.87B |
| Gross Profit | $ 109.13B | $ 108.03B | $ 96.20B | $ 81.30B | $ 60.80B |
| Operating Income | $ 5.99B | $ 10.64B | $ 9.13B | $ 9.32B | $ -4.94B |
| EBITDA | $ 10.53B | $ 10.79B | $ 13.37B | $ 10.78B | $ -254.11M |
| Net Income | $ -116.64B | $ 2.79B | $ 5.73B | $ 70.06B | $ 32.47B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 22.41B | $ 38.45B | $ 37.44B | $ 19.89B | $ 34.19B |
| Total Assets | $ 195.41B | $ 363.45B | $ 335.92B | $ 317.39B | $ 220.32B |
| Total Debt | $ 6.00B | $ 38.99B | $ 37.96B | $ 39.49B | $ 48.01B |
| Net Debt | $ -15.88B | $ 1.07B | $ 1.06B | $ 20.14B | $ 14.35B |
| Total Liabilities | $ 49.11B | $ 114.02B | $ 107.71B | $ 110.28B | $ 93.39B |
| Stockholders' Equity | $ 146.30B | $ 249.44B | $ 228.22B | $ 207.12B | $ 126.94B |
| Cash Flow | |||||
| Free Cash Flow | $ 3.86B | $ -399.26M | $ 2.15B | $ -13.24B | $ -26.23B |
| Operating Cash Flow | $ 5.32B | $ 2.38B | $ 5.44B | $ -1.29B | $ 7.78B |
| Investing Cash Flow | $ -2.42B | $ -889.45M | $ 3.26B | $ -15.28B | $ -30.39B |
| Financing Cash Flow | $ -18.93B | $ -483.95M | $ 8.85B | $ 2.27B | $ 30.34B |
Currency in KRW